Background: Broadmann Area 10 (BA10) is the largest cytoarchitectonic region of the human cortex and perhaps the most evolutionarily advanced, yet it remains poorly understood, in part due to the complexity of its integrative functions. Bipolar disorder (BP) and schizophrenia (SCHIZ) are two disorders that share symptomatology and genetic risk. The average onset of BP and SCHIZ coincides with the adolescent pruning of BA10 grey matter, suggesting a potential role for BA10 dysfunction in the disorders. In this study, we investigated the role of neurotransmission-related gene expression in BA10 in BP and SCHIZ.
Methods: We performed qPCR to measure the expression of 115 neurotransmission-related targets in control, BP, and SCHIZ post-mortem samples (n=72). We chose this method for its high sensitivity to detect low-level expression. We then bolstered our findings by performing a meta-analysis of publicly-released BA10 microarray data (n=101) and identified sources of convergence with our qPCR results. To improve our interpretation of diagnosis effects, we compiled an unusually large database of clinical metadata for our qPCR samples. We used this data to explore the relationship between BA10 gene expression, therapeutics, substances of abuse, and symptom profiles, and validated these exploratory findings with publicly-available datasets.
Results: Using these convergent sources of evidence, we identified 20 neurotransmission-related genes that were differentially expressed in BP and SCHIZ in BA10. These results include a large down-regulation in BP and SCHIZ of two important therapeutic targets with low-levels of expression, HTR2B and DRD4, as well as other findings related to dopaminergic, GABA-ergic and astrocytic function. We also found evidence that therapeutics may produce differential expression that opposes the effects of diagnosis. In contrast, substances of abuse may be associated with similar effects on BA10 gene expression as BP and SCHIZ, potentially amplifying diagnosis-related dysregulation.